Retina

According to the company, the deal expands its European footprint into Spain and Portugal.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.

Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.

The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Faricimab could lower treatment burden for patients compared to aflibercept

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

Quantitative optical coherence tomography angiography analysis using the index is a useful biomarker for detecting early diabetic retinopathy.

Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

Dr Jennifer Lim presents two case studies demonstrating the application of the personalized treatment interval algorithm from the YOSEMITE and RHINE clinical trials for faricimab in DME.

Dr Jennifer Lim reviews the personalized treatment algorithm in the YOSEMITE and RHINE trials for faricimab in DME, discussing visual and anatomic outcomes with the treat and extend strategy.

Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.

Dr Ala Moshiri provides an overview of current treatment options for diabetic macular oedema.

Nicholas Volpe, MD shares insights from his talk titled "Optic Neuropathy Versus Maculopathy" at the European Society of Ophthalmology Congress being held in Prague.

As more countries receive approval for the use of faricimab, patients are going to continue to have good visual outcomes

RGC replacement represents a more formidable challenge.

Geographic atrophy is now a major research target.

Dr Edmund Arthur shares his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Dr T.Y. Alvin Liu talks about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

Dr Caroline Baumal talks about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.